thalidomide has been researched along with Alopecia Circumscripta in 9 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that reduces pro-inflammatory cytokine production." | 6.90 | A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. ( Baum, D; Guttman-Yassky, E; Hashim, P; Karalekas, R; Kimmel, G; Lebwohl, MG; Mansouri, Y; Mikhaylov, D; Nia, J; Pavel, A; Singer, G; Taliercio, M; Vekaria, AS; Yao, C, 2019) |
| "Thalidomide has been used in the treatment of many dermatological disorders." | 5.32 | The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata. ( Namazi, MR, 2003) |
| "Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that reduces pro-inflammatory cytokine production." | 2.90 | A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. ( Baum, D; Guttman-Yassky, E; Hashim, P; Karalekas, R; Kimmel, G; Lebwohl, MG; Mansouri, Y; Mikhaylov, D; Nia, J; Pavel, A; Singer, G; Taliercio, M; Vekaria, AS; Yao, C, 2019) |
| "Thalidomide has been used in the treatment of many dermatological disorders." | 1.32 | The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata. ( Namazi, MR, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chhabra, G | 1 |
| Verma, P | 1 |
| Sakakibara, M | 1 |
| Shimoyama, H | 1 |
| Nomura, M | 1 |
| Nakashima, C | 1 |
| Hirabayashi, M | 1 |
| Sei, Y | 1 |
| Kuwano, Y | 1 |
| Liu, LY | 1 |
| King, BA | 1 |
| Magdaleno-Tapial, J | 1 |
| Valenzuela-Oñate, C | 1 |
| Sánchez-Carazo, JL | 1 |
| Alegre-de Miquel, V | 1 |
| Mikhaylov, D | 1 |
| Pavel, A | 1 |
| Yao, C | 1 |
| Kimmel, G | 1 |
| Nia, J | 1 |
| Hashim, P | 1 |
| Vekaria, AS | 1 |
| Taliercio, M | 1 |
| Singer, G | 1 |
| Karalekas, R | 1 |
| Baum, D | 1 |
| Mansouri, Y | 1 |
| Lebwohl, MG | 1 |
| Guttman-Yassky, E | 1 |
| Laufer Britva, R | 1 |
| Keren, A | 2 |
| Paus, R | 2 |
| Gilhar, A | 2 |
| Shemer, A | 1 |
| Ullmann, Y | 1 |
| Namazi, MR | 1 |
| Frank, PJ | 1 |
1 trial available for thalidomide and Alopecia Circumscripta
| Article | Year |
|---|---|
A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Topics: Adult; Aged; Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Middle | 2019 |
8 other studies available for thalidomide and Alopecia Circumscripta
| Article | Year |
|---|---|
Steroid-resistant alopecia totalis in a child successfully treated with oral apremilast and platelet-rich plasma therapy.
Topics: Administration, Oral; Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Child; Combined Moda | 2019 |
Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata.
Topics: Alopecia Areata; Humans; Male; Phosphodiesterase 4 Inhibitors; Severity of Illness Index; Thalidomid | 2019 |
Lack of efficacy of apremilast in 9 patients with severe alopecia areata.
Topics: Adolescent; Adult; Age Factors; Aged; Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Dose | 2017 |
Improvement of alopecia areata with apremilast.
Topics: Alopecia Areata; Female; Humans; Middle Aged; Off-Label Use; Phosphodiesterase 4 Inhibitors; Thalido | 2019 |
Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata.
Topics: Alopecia Areata; Animals; Mice; Piperidines; Pyrimidines; Pyrroles; Thalidomide | 2020 |
The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo.
Topics: Alopecia Areata; Animals; Anti-Inflammatory Agents, Non-Steroidal; CD4-Positive T-Lymphocytes; CD8-P | 2015 |
The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata.
Topics: Alopecia Areata; Animals; Humans; Immunosuppressive Agents; Mice; Models, Theoretical; Thalidomide | 2003 |
Scleroderma.
Topics: Alopecia Areata; Azathioprine; Biopsy; Bursitis; Colchicine; Diagnosis, Differential; Drug Therapy, | 2001 |